Glecaprevir-pibrentasvir to Treat Chronic Hepatitis C Virus Infection in Asia: Two Multicentre, Phase 3 Studies-a Randomised, Double-Blind Study (VOYAGE-1) and an Open-Label, Single-Arm Study (VOYAGE-2)
Lai Wei,Guiqiang Wang,Negar N. Alami,Wen Xie,Jeong Heo,Qing Xie,Mingxiang Zhang,Yoon Jun Kim,Seng Gee Lim,Linda M. Fredrick,Wenjing Lu,Wei Liu,Hari Kalluri,Preethi Krishnan,Rakesh Tripathi,Niloufar Mobashery,Margaret Burroughs,Armen Asatryan,Jidong Jia,Jinlin Hou
DOI: https://doi.org/10.1016/s2468-1253(20)30086-8
2020-01-01
SSRN Electronic Journal
Abstract:BackgroundGlecaprevir–pibrentasvir results in high rates of sustained virological response in patients with chronic hepatitis C virus (HCV) genotype 1–6 infection. Data for glecaprevir–pibrentasvir in non-Japanese Asian patients have been minimal. The aim of these studies was to assess the efficacy and safety of glecaprevir–pibrentasvir in treatment-naive and treatment-experienced Asian patients with chronic HCV genotype 1–6 infection without cirrhosis (VOYAGE-1) and with compensated cirrhosis (VOYAGE-2).MethodsWe did two phase 3 studies in treatment-naive and treatment-experienced patients with chronic HCV genotype 1–6 infection. VOYAGE-1 was a randomised, double-blind, placebo-controlled study that recruited patients without cirrhosis at 47 sites across China, South Korea, and Singapore. Randomisation was 2:1 with a fixed block size of three and stratified by geographical region and HCV genotype. Investigators, study site personnel, the study sponsor, and patients were masked to treatment allocation. VOYAGE-2 was a single-arm, open-label study that recruited patients with compensated cirrhosis at 34 sites across China and South Korea. Glecaprevir (300 mg) and pibrentasvir (120 mg) or placebo (VOYAGE-1, 2:1 ratio), administered as three tablets daily, was given for 8 weeks in patients without cirrhosis and for 12 weeks in those with cirrhosis (and for 16 weeks in treatment-experienced patients with genotype 3). The primary efficacy endpoint was the proportion of patients with a sustained virological response, defined as HCV RNA below the lower limit of quantification 12 weeks after the last dose of glecaprevir–pibrentasvir. We analysed efficacy and safety in all patients who received at least one dose of the study drug. These trials are registered with ClinicalTrials.gov, NCT03222583 (VOYAGE-1) and NCT03235349 (VOYAGE-2); both trials have been completed. This Article reports the results of the primary analysis for each study, undertaken when all patients who received glecaprevir–pibrentasvir (during the double-blind period in VOYAGE-1) had been followed up for 12 weeks following their last dose of study drug. Data from the double-blind period for placebo patients in VOYAGE-1 are also summarised.FindingsBetween Oct 4, 2017, and April 20, 2018, 546 patients with chronic HCV without cirrhosis were randomly assigned to treatment (363 to glecaprevir–pibrentasvir, 183 to placebo) in VOYAGE-1. One patient withdrew consent and did not receive treatment with glecaprevir–pibrentasvir. 352 of 362 patients who received glecaprevir–pibrentasvir achieved SVR12 (97·2% [95% CI 95·5–98·9]). Of 160 patients with compensated cirrhosis who were enrolled in VOYAGE-2 between Sept 29, 2017, and June 14, 2018, 159 of 160 achieved SVR12 (99·4%, 95% CI 98·2–100·0). 20 patients with HCV genotype 3b across both trials received glecaprevir–pibrentasvir; six of these patients were among the 11 patients who did not achieve SVR12. Upper respiratory tract infection was the most common adverse event (35 [10%] of 362 receiving glecaprevir–pibrentasvir and 18 [10%] of 183 receiving placebo in VOYAGE-1; 19 [12%] of 160 in VOYAGE-2). For patients receiving glecaprevir–pibrentasvir, serious adverse events occurred in three (<1%) of 362 patients in VOYAGE-1 and five (3%) of 160 patients in VOYAGE-2. Grade 3–4 adverse events in patients receiving glecaprevir–pibrentasvir occurred in five (1%) of 362 patients in VOYAGE-1 and six (4%) of 160 patients in VOYAGE-2; each type of event was experienced by at most one patient within a study. One patient with cirrhosis discontinued study drug because of an adverse event.InterpretationGlecaprevir–pibrentasvir showed high efficacy and an acceptable safety profile in these studies although responses were less common in the few patients with HCV genotype 3b. The results support the use of glecaprevir–pibrentasvir in these Asian populations.FundingAbbVie.